Oral nicotine products, such as nicotine pouches and snus, are now regulated as cigarettes or cut tobacco in China. Photo credit: L.V. Olavi Rantala, CC2.0.
China’s top tobacco regulator has issued its first formal rules governing oral nicotine products, bringing nicotine pouches and other smokeless tobacco items under China’s state tobacco monopoly for the first time.
The State Tobacco Monopoly Administration (STMA) dated the announcement January 6 and released it publicly on January 9, with immediate effect. The move clearly defines the regulatory status of oral nicotine products, which previously operated in a legal gray area, and marks a major shift in China’s approach to regulating nicotine.
Under the new framework, STMA defines “smokeless tobacco products” as nicotine-containing products consumed orally, nasally, or through external use without producing smoke. The definition explicitly covers nicotine pouches, oral strips and patches, snus, chewing tobacco, and snuff. Regulators have now formally recognized oral nicotine as a distinct product category within China’s tobacco control system.
The most significant provision concerns how authorities classify these products. STMA will regulate smokeless tobacco as either cigarettes or cut tobacco, not under China’s e-cigarette rules. As a result, oral nicotine products will fall under the country’s traditional tobacco monopoly system, which tightly controls production, branding, and distribution through state-run entities.
The announcement also places smokeless tobacco products under China’s “restricted” industrial policy category. This classification subjects factory construction, capacity expansion, and related investment to strict regulatory approval. Oversight will extend beyond product sales to manufacturing scale and capital entry.
By aligning product definitions, regulatory classification, and industrial policy, regulators have fully absorbed oral nicotine products into China’s existing tobacco production and control framework. Cigarettes and cut tobacco already operate under a highly centralized monopoly, and oral nicotine products will now follow the same structure.
This shift could make it difficult for privately led manufacturing and branding models to survive in China’s domestic market. As licensing rules, capacity allocation, and market access conditions change, the competitive landscape could face significant restructuring.